Updates in Chronic Lymphocytic Leukemia
Recorded on: April 4, 2023
Recording will be available soon.
Target Audience
This CE activity is intended for hematologist/oncologists, oncology nurses, social workers, and other healthcare professionals involved in the care of patients with chronic lymphocytic leukemia.
Educational Objectives
After completing this CE activity, the participant should be better able to:
- Describe the types and subtypes of chronic lymphocytic leukemia (CLL)
- Identify tests used to diagnose disease and monitor treatment
- Explain approved and emerging treatment options for CLL
- Describe strategies to manage treatment side effects as well as long-term and late effects of treatments
- Review vaccination strategies, the impact of COVID-19, and importance of screening for secondary cancers
- Describe the role of the multidisciplinary healthcare team in managing patients with CLL
Faculty
William Wierda, MD, PhD
Professor of Medicine
Section Head – CLL
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX
Jill Miller, MS, PA-C
Manager, Advanced Practice Providers
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX
Accreditation, Credit and Support
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and The Leukemia & Lymphoma Society. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Medical Learning Institute, Inc. (MLI) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development Contact Hours
Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under Provider Number CEP 5832 to award 1.0 continuing education contact hour through the California Board of Registered Nursing.
Social Work Credit Designation
The Leukemia & Lymphoma Society (LLS) Provider Number 1105, is approved as an ACE provider to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Regulatory boards are the final authority on courses accepted for continuing education credit. ACE provider approval period: 12/10/2020-12/10/2023. Social workers completing this course receive 1.0 clinical continuing education credits.
The Leukemia & Lymphoma Society (LLS) is recognized by the New York State Education Departments State Board for Social Work as an approved provider of continuing education for licensed social workers #0117. LLS maintains responsibility for the program. Social workers will receive 1.0 clinical CE contact hours for this activity.
Interprofessional Continuing Education Credit
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.
Method of Participation
Participants must review the webcast in its entirety and complete the evaluation. After completing this process you will receive your certificate by email.
All continuing education credits are provided free of charge.
Providers
This activity is provided by Medical Learning Institute, Inc and The Leukemia & Lymphoma Society.
Supporters
There is no commercial support associated with this CE activity.
For questions, concerns, or for assistance for people with disabilities or grievances, please contact us at ProfEducation@LLS.org.